Immunotherapy for Alzheimer's Disease: Current Scenario and Future Perspectives.

Usman, MB; Bhardwaj, S; Roychoudhury, S; Kumar, D; Alexiou, A; Kumar, P; Ambasta, RK; Prasher, P; Shukla, S; Upadhye, V; Khan, FA; Awasthi, R; Shastri, MD; Singh, SK; Gupta, G; Chellappan, DK; Dua, K; Jha, SK; Ruokolainen, J; Kesari, KK; Ojha, S; Jha, NK

Immunotherapy for Alzheimer's Disease: Current Scenario and Future Perspectives.

Usman, MB Bhardwaj, S Roychoudhury, S Kumar, D Alexiou, A Kumar, P Ambasta, RK Prasher, P Shukla, S

Upadhye, V Khan, FA Awasthi, R Shastri, MD Singh, SK Gupta, G Chellappan, DK Dua, K

Jha, SK Ruokolainen, J Kesari, KK Ojha, S Jha, NK

Permalink

Publisher:: SPRINGER BASEL AG
Publication Type:: Journal Article
Citation:: J Prev Alzheimers Dis, 2021, 8, (4), pp. 534-551
Issue Date:: 2021

Closed Access

	Filename	Description	Size
	Alzheimer.pdf	Published version	5.22 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Usman, MB
dc.contributor.author	Bhardwaj, S
dc.contributor.author	Roychoudhury, S
dc.contributor.author	Kumar, D
dc.contributor.author	Alexiou, A
dc.contributor.author	Kumar, P
dc.contributor.author	Ambasta, RK
dc.contributor.author	Prasher, P
dc.contributor.author	Shukla, S https://orcid.org/0000-0002-5796-0171
dc.contributor.author	Upadhye, V
dc.contributor.author	Khan, FA
dc.contributor.author	Awasthi, R
dc.contributor.author	Shastri, MD
dc.contributor.author	Singh, SK
dc.contributor.author	Gupta, G
dc.contributor.author	Chellappan, DK
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159
dc.contributor.author	Jha, SK
dc.contributor.author	Ruokolainen, J
dc.contributor.author	Kesari, KK
dc.contributor.author	Ojha, S
dc.contributor.author	Jha, NK
dc.date.accessioned	2022-06-16T03:53:30Z
dc.date.available	2022-06-16T03:53:30Z
dc.date.issued	2021
dc.identifier.citation	J Prev Alzheimers Dis, 2021, 8, (4), pp. 534-551
dc.identifier.issn	2274-5807
dc.identifier.issn	2426-0266
dc.identifier.uri	http://hdl.handle.net/10453/158208
dc.description.abstract	Alzheimer's disease (AD) is a global health concern owing to its complexity, which often poses a great challenge to the development of therapeutic approaches. No single theory has yet accounted for the various risk factors leading to the pathological and clinical manifestations of dementia-type AD. Therefore, treatment options targeting various molecules involved in the pathogenesis of the disease have been unsuccessful. However, the exploration of various immunotherapeutic avenues revitalizes hope after decades of disappointment. The hallmark of a good immunotherapeutic candidate is not only to remove amyloid plaques but also to slow cognitive decline. In line with this, both active and passive immunotherapy have shown success and limitations. Recent approval of aducanumab for the treatment of AD demonstrates how close passive immunotherapy is to being successful. However, several major bottlenecks still need to be resolved. This review outlines recent successes and challenges in the pursuit of an AD vaccine.
dc.format	Print
dc.language	eng
dc.publisher	SPRINGER BASEL AG
dc.relation.ispartof	J Prev Alzheimers Dis
dc.relation.isbasedon	10.14283/jpad.2021.52
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject.mesh	Alzheimer Disease
dc.subject.mesh	Alzheimer Vaccines
dc.subject.mesh	Antibodies, Monoclonal, Humanized
dc.subject.mesh	Cognitive Dysfunction
dc.subject.mesh	Humans
dc.subject.mesh	Immunotherapy
dc.subject.mesh	Plaque, Amyloid
dc.subject.mesh	Humans
dc.subject.mesh	Alzheimer Disease
dc.subject.mesh	Alzheimer Vaccines
dc.subject.mesh	Immunotherapy
dc.subject.mesh	Plaque, Amyloid
dc.subject.mesh	Antibodies, Monoclonal, Humanized
dc.subject.mesh	Cognitive Dysfunction
dc.title	Immunotherapy for Alzheimer's Disease: Current Scenario and Future Perspectives.
dc.type	Journal Article
utslib.citation.volume	8
utslib.location.activity	Switzerland
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Public Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health/GSH.Pharmacy
utslib.copyright.status	closed_access	*
dc.date.updated	2022-06-16T03:53:21Z
pubs.issue	4
pubs.publication-status	Published
pubs.volume	8
utslib.citation.issue	4

Abstract:

Alzheimer's disease (AD) is a global health concern owing to its complexity, which often poses a great challenge to the development of therapeutic approaches. No single theory has yet accounted for the various risk factors leading to the pathological and clinical manifestations of dementia-type AD. Therefore, treatment options targeting various molecules involved in the pathogenesis of the disease have been unsuccessful. However, the exploration of various immunotherapeutic avenues revitalizes hope after decades of disappointment. The hallmark of a good immunotherapeutic candidate is not only to remove amyloid plaques but also to slow cognitive decline. In line with this, both active and passive immunotherapy have shown success and limitations. Recent approval of aducanumab for the treatment of AD demonstrates how close passive immunotherapy is to being successful. However, several major bottlenecks still need to be resolved. This review outlines recent successes and challenges in the pursuit of an AD vaccine.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/158208